

Date of last issue: 2020/10/10

Enalapril Formulation

Version

Revision Date:

SDS Number:

2.8	2021/04/09		5 Number: 1742-00012	Date of first issue: 2020/10/10 Date of first issue: 2016/06/07
1. PRODU	JCT AND COMPANY ID	ENT	IFICATION	
Prod	uct name	:	Enalapril Form	nulation
Manu	ufacturer or supplier's c	letai	ils	
Com	pany	:	Organon & Co	
Addro	ess	:	JL Raya Pand Pandaan, Jaw	aan KM. 48 a Timur - Indonesia
Telep	phone	:	551-430-6000	
Emei	rgency telephone number	r:	215-631-6999	
E-ma	ail address	:	EHSSTEWAR	D@organon.com
Reco	ommended use of the cl	hem	ical and restric	ctions on use
Reco	mmended use	:	Pharmaceutica	al
2. HAZAR	RDS IDENTIFICATION			
GHS	Classification			
Repr	oductive toxicity	:	Category 1A	
	ific target organ toxicity - ated exposure	:	Category 2 (K	idney, Cardio-vascular system)
GHS	label elements			
Haza	rd pictograms	:		
Signa	al word	:	Danger	
Haza	ard statements	:	H373 May cau	amage the unborn child. ise damage to organs (Kidney, Cardio-vascular gh prolonged or repeated exposure.
Preca	autionary statements	:	P202 Do not h and understoo P260 Do not b P280 Wear pro- tion/ face prote Response:	reathe dust. otective gloves/ protective clothing/ eye protec-





Version	Revision Date:	SDS Number:	Date of last issue: 2020/10/10
2.8	2021/04/09	734742-00012	Date of first issue: 2016/06/07

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin. May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Starch	9005-25-8	>= 10 -< 30
(S)-1-[N-[1-(Ethoxycarbonyl)-3-phenylpropyl]-L- alanyl]-L-proline maleate	76095-16-4	>= 1 -< 10

4. FIRST AID MEASURES

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	May damage the unborn child. May cause damage to organs through prolonged or repeated exposure. Contact with dust can cause mechanical irritation or drying of
Protection of first-aiders	:	and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.



Enalapril Formulation

Version 2.8	Revision Date: 2021/04/09		DS Number: 4742-00012	Date of last issue: 2020/10/10 Date of first issue: 2016/06/07			
5. FIREF	FIGHTING MEASURES						
Suitable extinguishing media Unsuitable extinguishing media		:	 Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical None known. 				
Spe	Specific hazards during fire- fighting		concentrations, an potential dust exp	dust; fine dust dispersed in air in sufficient nd in the presence of an ignition source is a losion hazard. pustion products may be a hazard to health.			
Haz ucts	zardous combustion prod-	:	Carbon oxides Metal oxides				
Specific extinguishing meth- ods		:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to d so. Evacuate area.				
	ecial protective equipment firefighters	:		e, wear self-contained breathing apparatus. ective equipment.			
6. ACCI	DENTAL RELEASE MEAS	SUF	RES				
tive	Personal precautions, protec- tive equipment and emer- gency procedures		Follow safe handl	ective equipment. ing advice (see section 7) and personal pro- recommendations (see section 8).			
Env	Environmental precautions		Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.				
	hods and materials for tainment and cleaning up	:	tainer for disposal Avoid dispersal of with compressed Dust deposits sho es, as these may leased into the att Local or national to posal of this mate employed in the c mine which regula Sections 13 and 1	dust in the air (i.e., clearing dust surfaces			

7. HANDLING AND STORAGE

- **Technical measures**
- : Static electricity may accumulate and ignite suspended dust



Enalapril Formulation

Vers 2.8	sion	Revision Date: 2021/04/09	SDS Number: 734742-00012	Date of last issue: 2020/10/10 Date of first issue: 2016/06/07
			and bonding, or	te precautions, such as electrical grounding inert atmospheres.
	Local/T	otal ventilation	: If sufficient venti ventilation.	lation is unavailable, use with local exhaust
Advice on safe handling		on safe handling	Handle in accord practice, based sessment Keep container Minimize dust go Keep container Keep away from Take precaution Do not eat, drink	dust. th eyes. ughly after handling. dance with good industrial hygiene and safety on the results of the workplace exposure as-
	Conditi	ons for safe storage	Store locked up. Keep tightly close	
	Materia	als to avoid		n the following product types:

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Starch	9005-25-8	NAB	10 mg/m3	ID OEL
	Further information: Not classified as carcinogenic to humar enough data to classify these materials as carcinogenic to h mans or animals			
		TWA	10 mg/m3	ACGIH
(S)-1-[N-[1-(Ethoxycarbonyl)-3- phenylpropyl]-L-alanyl]-L- proline maleate	76095-16-4	TWA	50 μg/m3 (OEB 3)	Internal
		Wipe limit	500 µg/100 cm ²	Internal

Engineering measures : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.



Enalapril Formulation

Version 2.8	Revision Date: 2021/04/09	SDS Number: 734742-00012	Date of last issue: 2020/10/10 Date of first issue: 2016/06/07					
Pers	onal protective equip	ment						
Resp	Respiratory protection		ocal exhaust ventilation is not available or expo- ment demonstrates exposures outside the rec- guidelines, use respiratory protection.					
	ilter type d protection		Particulates type					
Ν	laterial	: Chemical-re	sistant gloves					
Remarks Eye protection		If the work e mists or aero Wear a face	uble gloving. glasses with side shields or goggles. nvironment or activity involves dusty conditions, psols, wear the appropriate goggles. shield or other full face protection if there is a direct contact to the face with dusts, mists, or					
Skin	and body protection	Additional bo task being p posable suit	n or laboratory coat. ody garments should be used based upon the erformed (e.g., sleevelets, apron, gauntlets, dis- s) to avoid exposed skin surfaces. iate degowning techniques to remove potentially d clothing.					
Hygiene measures		: If exposure t eye flushing ing place. When using Wash contai The effective engineering appropriate industrial hys	If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the work- ing place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.					

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Colour	:	white
Odour	:	No data available
Odour Threshold	:	No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, han-



Enalapril Formulation

Version 2.8	Revision Date: 2021/04/09		S Number: 742-00012	Date of last issue: 2020/10/10 Date of first issue: 2016/06/07
			dling or other me	ans.
Fla	mmability (liquids)	:	No data available)
	Upper explosion limit / Upper flammability limit		No data available)
	ver explosion limit / Lower nmability limit	:	No data available)
Vap	oour pressure	:	Not applicable	
Rel	ative vapour density	:	Not applicable	
Rel	ative density	:	No data available)
Der	nsity	:	No data available)
	ubility(ies) Water solubility	:	No data available	9
	tition coefficient: n-	:	Not applicable	
	anol/water o-ignition temperature	:	No data available	2
Dec	composition temperature	:	No data available)
	cosity Viscosity, kinematic	:	Not applicable	
Exp	losive properties	:	Not explosive	
Oxi	dizing properties	:	The substance of	r mixture is not classified as oxidizing.
Par	ticle size	:	No data available	9

10. STABILITY AND REACTIVITY

Reactivity Chemical stability Possibility of hazardous reac- tions	:	Not classified as a reactivity hazard. Stable under normal conditions. May form explosive dust-air mixture during processing, han- dling or other means. Can react with strong oxidizing agents.
Conditions to avoid Incompatible materials	:	Heat, flames and sparks. Avoid dust formation. Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of : Inhalation

Enalapril Formulation



ersion 8	Revision Date: 2021/04/09		9S Number: 4742-00012	Date of last issue: 2020/10/10 Date of first issue: 2016/06/07		
expos	exposure		Skin contact Ingestion Eye contact			
	toxicity					
	assified based on availa	adie	Information.			
	Product: Acute oral toxicity :		Acute toxicity est Method: Calculat	imate: > 2,000 mg/kg ion method		
<u>Comp</u>	oonents:					
Starc	h:					
Acute	oral toxicity	:	LD50 (Rat): > 5,0	LD50 (Rat): > 5,000 mg/kg		
Acute	dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg			
(S)-1-	[N-[1-(Ethoxycarbony])-3-	ohenvlpropyl]-L-a	alanyl]-L-proline maleate:		
	oral toxicity	:	LD50 (Rat): 2,000			
			LDLo (Rat): 1,77	5 mg/kg		
			LD50 (Mouse): 2	,000 - 3,500 mg/kg		
			LDLo (Mouse): 1	,000 mg/kg		
	toxicity (other routes of istration)	:	LD50 (Rat): 850 (Application Route			
			LD50 (Mouse): 7 Application Route			
			LD50 (Dog): > 10)0 mg/kg		
			LDLo (Dog): 200	mg/kg		
_	corrosion/irritation	. b . J -				
	assified based on availa	ela	information.			

Components:

(S)-1-[N-[1-(Ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-L-proline maleate:

Species	:	Rabbit
Result	:	No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Starch:		
Species	:	Rabbit
Result	:	No eye irritation



Enalapril Formulation

Version 2.8	Revision Date: 2021/04/09		S Number: 4742-00012	Date of last issue: 2020/10/10 Date of first issue: 2016/06/07
(S)- ′ Spe Res	cies	nyl)-3-j	bhenylpropyl] Rabbit Severe irritati	-L-alanyl]-L-proline maleate:
	piratory or skin sens	sitisatio	n	
-	sensitisation classified based on av	vailahle	information	
	piratory sensitisation		information.	
	classified based on av		information.	
Con	nponents:			
Star	ch:			
		:	Maximisation Skin contact Guinea pig negative	Test
(S)-2	1-[N-[1-(Ethoxycarbo	nyl)-3-j	ohenylpropyl]	-L-alanyl]-L-proline maleate:
Test	Type osure routes	:	Maximisation Skin contact Guinea pig	
Res	ult	:	Not a skin sei	nsitizer.
Geri	m cell mutagenicity			
Not	classified based on av	ailable	information.	
<u>Con</u>	nponents:			
Star	ch:			
Gen	otoxicity in vitro	:	Test Type: Ba Result: negat	acterial reverse mutation assay (AMES) ive
(S)-′	1-[N-[1-(Ethoxycarbo	nyl)-3-j	ohenylpropyl]	-L-alanyl]-L-proline maleate:
Gen	otoxicity in vitro	:	Test Type: Ba Result: negat	acterial reverse mutation assay (AMES)
			Test Type: In malian cells Result: negat	vitro sister chromatid exchange assay in mam-
			Test Type: Al Result: negat	kaline elution assay ive
Gen	otoxicity in vivo	:	cytogenetic a Species: Mou	se oute: Ingestion



Enalapril Formulation

/ersion 2.8	Revision Date: 2021/04/09	SDS Number: 734742-00012	Date of last issue: 2020/10/10 Date of first issue: 2016/06/07
		cytogenetic te Species: Mous	pute: Ingestion
	nogenicity assified based on ava	ailable information.	
<u>Comp</u>	oonents:		
(S)-1-	[N-[1-(Ethoxycarbor	yl)-3-phenylpropyl]-	L-alanyl]-L-proline maleate:
Speci		: Rat	
	ation Route	: Ingestion	
	sure time	: 106 weeks	
NOAE Resul		: 90 mg/kg body : negative	yweight
Speci	es	: Mouse	
	ation Route	: Ingestion	
	sure time	: 94 weeks	
NÔAE	EL	: 90 - 180 mg/kg	g body weight
Comp	lamage the unborn ch ponents: [N-[1-(Ethoxycarbor		L-alanyl]-L-proline maleate:
Effect	s on fertility	: Test Type: Fe	rtility
			male and female
			bute: Ingestion
			EL: 90 mg/kg body weight ects on fertility
Effect	s on foetal develop-	: Species: Rat	
ment		Developmenta	oute: Ingestion al Toxicity: NOAEL: 200 mg/kg body weight ects on foetal development
			oute: Ingestion al Toxicity: LOAEL: 1,200 mg/kg body weight
		Species: Rat Application Ro Developmenta	oute: Ingestion al Toxicity: LOAEL: 30 mg/kg body weight s on postnatal development, Effects on newbo
		Species: Rabb Application Ro	bit bute: Ingestion



Enalapril Formulation

rsion	Revision Date: 2021/04/09	SDS Numb 734742-000	
		Develop	Toxicity Maternal: LOAEL: 1 mg/kg body weight omental Toxicity: LOAEL: 1 mg/kg body weight Fetotoxicity, Maternal toxicity observed., No teratoger s
Repro sessn	oductive toxicity - As- nent		evidence of adverse effects on development from epidemiological studies.
	- single exposure assified based on ava	ilable informati	on.
STOT	- repeated exposure	2	
	ause damage to orga		rdio-vascular system) through prolonged or repeated
Com	oonents:		
		vl)-3-phonylpr	opyl]-L-alanyl]-L-proline maleate:
	t Organs		Cardio-vascular system
	ssment		damage to organs through prolonged or repeated
Repe	ated dose toxicity		
Com	oonents:		
Starc	h:		
Otarc			
Speci NOAE Applic	es EL cation Route sure time	: Rat : >= 2,00 : Skin col : 28 Days : OECD	ntact
Speci NOAE Applic Expos Metho	es EL cation Route sure time od	: >= 2,00 : Skin col : 28 Days : OECD	ntact Fest Guideline 410
Speci NOAE Applic Expos Metho	es EL cation Route sure time od [N-[1-(Ethoxycarbon	: >= 2,00 : Skin cor : 28 Days : OECD ⊺ yl)-3-phenylpr	ntact
Speci NOAE Applic Expos Metho	es EL cation Route sure time od [N-[1-(Ethoxycarbon es	: >= 2,00 : Skin col : 28 Days : OECD	ntact Fest Guideline 410 opyl]-L-alanyl]-L-proline maleate:
Speci NOAE Applic Expos Metho (S)-1- Speci NOAE LOAE	es EL cation Route sure time od [N-[1-(Ethoxycarbon es EL EL	: >= 2,00 : Skin cor : 28 Days : OECD □ yl)-3-phenylpr : Dog	ntact Fest Guideline 410 opyl]-L-alanyl]-L-proline maleate:
Speci NOAE Applic Expos Metho (S)-1- Speci NOAE LOAE Applic	es EL cation Route sure time od [N-[1-(Ethoxycarbon es EL EL cation Route	 : >= 2,00 : Skin col : 28 Days : OECD : Ingestion 	ntact Fest Guideline 410 opyl]-L-alanyl]-L-proline maleate: g
Speci NOAE Applic Expos Metho (S)-1- Speci NOAE LOAE Applic Expos	es EL cation Route sure time od [N-[1-(Ethoxycarbon es EL EL cation Route sure time	 : >= 2,00 : Skin col : 28 Days : OECD : OECD : Dog : 15 mg/k : 30 mg/k : Ingestio : 1 yr 	ntact Fest Guideline 410 opyl]-L-alanyl]-L-proline maleate: g
Speci NOAE Applic Expos Metho (S)-1- Speci NOAE LOAE Applic Expos	es EL cation Route sure time od [N-[1-(Ethoxycarbon es EL EL cation Route	 : >= 2,00 : Skin col : 28 Days : OECD : Ingestion 	ntact Fest Guideline 410 opyl]-L-alanyl]-L-proline maleate: g
Speci NOAE Applic Expos Metho (S)-1- Speci NOAE LOAE Applic Expos	es EL cation Route sure time od [N-[1-(Ethoxycarbon es EL EL cation Route sure time et Organs	 : >= 2,00 : Skin col : 28 Days : OECD : OECD : Dog : 15 mg/k : 30 mg/k : Ingestio : 1 yr 	ntact Fest Guideline 410 opyl]-L-alanyl]-L-proline maleate: g
Speci NOAE Applic Expos Metho (S)-1- Speci NOAE Applic Expos Targe Speci NOAE	es EL cation Route sure time od [N-[1-(Ethoxycarbon es EL EL cation Route sure time et Organs es	 >= 2,00 Skin col 28 Days OECD yl)-3-phenylpr Dog 15 mg/k 30 mg/k Ingestion 1 yr Kidney Rat 90 mg/k 	ntact Fest Guideline 410 opyl]-L-alanyl]-L-proline maleate: g g n
Speci NOAE Applic Expos Metho (S)-1- Speci NOAE LOAE Applic Expos Targe Speci NOAE Applic	es EL cation Route sure time od [N-[1-(Ethoxycarbon es EL cation Route sure time et Organs EL cation Route cation Route	 >= 2,00 Skin col 28 Days OECD yl)-3-phenylpr Dog 15 mg/k 30 mg/k Ingestion 1 yr Kidney Rat 90 mg/k Oral 	ntact Fest Guideline 410 opyl]-L-alanyl]-L-proline maleate: g g n
Speci NOAE Applic Expos Metho (S)-1- Speci NOAE LOAE Applic Expos Targe Speci NOAE Applic	es EL cation Route sure time od [N-[1-(Ethoxycarbon es EL cation Route sure time et Organs EL cation Route sure time	 >= 2,00 Skin col 28 Days OECD yl)-3-phenylpr Dog 15 mg/k 30 mg/k Ingestio 1 yr Kidney Rat 90 mg/k Oral 1 yr 	ntact Fest Guideline 410 opyl]-L-alanyl]-L-proline maleate: g g n
Speci NOAE Applic Expos Metho (S)-1- Speci NOAE Applic Expos Targe Speci NOAE Applic Expos Rema	es EL cation Route sure time od [N-[1-(Ethoxycarbon es EL cation Route sure time of Organs es EL cation Route sure time isure time sure time sure time	 >= 2,00 Skin col 28 Days OECD yl)-3-phenylpr Dog 15 mg/k 30 mg/k Ingestion 1 yr Kidney Rat 90 mg/k Oral 1 yr No sign 	rest Guideline 410 opyl]-L-alanyl]-L-proline maleate: g g n g ificant adverse effects were reported
Speci NOAE Applic Expos Metho (S)-1- Speci NOAE LOAE Applic Expos Targe Speci NOAE Applic Expos	es EL cation Route sure time od [N-[1-(Ethoxycarbon es EL cation Route sure time ot Organs es EL cation Route sure time arks es	 >= 2,00 Skin col 28 Days OECD yl)-3-phenylpr Dog 15 mg/k 30 mg/k Ingestio 1 yr Kidney Rat 90 mg/k Oral 1 yr 	rest Guideline 410 opyl]-L-alanyl]-L-proline maleate: g g n g ificant adverse effects were reported
Speci NOAE Applic Expos Metho (S)-1- Speci NOAE Applic Expos Targe Speci NOAE Applic Expos Rema Speci NOAE	es EL cation Route sure time od [N-[1-(Ethoxycarbon es EL cation Route sure time et Organs es EL cation Route sure time trks es EL cation Route	 >= 2,00 Skin col 28 Days OECD yl)-3-phenylpr Dog 15 mg/k 30 mg/k Ingestio 1 yr Kidney Rat 90 mg/k Oral 1 yr No sign Monkey 30 mg/k Oral 	rest Guideline 410 opyl]-L-alanyl]-L-proline maleate: g g n g ificant adverse effects were reported g
Speci NOAE Applic Expos Metho (S)-1- Speci NOAE Applic Expos Targe Speci NOAE Applic Expos Rema Speci NOAE	es EL cation Route sure time od [N-[1-(Ethoxycarbon es EL cation Route sure time et Organs es EL cation Route sure time urks es EL cation Route sure time time time time sure time	 >= 2,00 Skin col 28 Days OECD yl)-3-phenylpr Dog 15 mg/k 30 mg/k Ingestion 1 yr Kidney Rat 90 mg/k Oral 1 yr No sign Monkey 30 mg/k Oral 1 Monther 	rest Guideline 410 opyl]-L-alanyl]-L-proline maleate: g g n g ificant adverse effects were reported g



Enalapril Formulation

Version 2.8	Revision Date: 2021/04/09	SDS Nu 734742-		Date of last issue: 2020/10/10 Date of first issue: 2016/06/07
-	ration toxicity lassified based on availa	ble inforn	nation.	
Expe	rience with human exp	osure		
Com	ponents:			
(S)-1-	-[N-[1-(Ethoxycarbonyl)-3-pheny	/lpropyl]-L	-alanyl]-L-proline maleate:
Inges		: Targ Sym Blurr ing,	et Organs: ptoms: hyp ed vision, I Weakness,	Cardio-vascular system otension, Cough, Dizziness, Headache, Fatigue, Oedema, Nausea, hyperkalemia, faint-
	oxicity ponents:			
Com	ponents:			
• •				-alanyl]-L-proline maleate:
Toxic	ity to fish	Expo	osure time:	les promelas (fathead minnow)): > 1,000 mg/l 96 h Test Guideline 203
	ity to daphnia and other tic invertebrates	Expo	osure time:	magna (Water flea)): 346 mg/l 48 h Test Guideline 202
Toxic	ity to microorganisms	Expo Test	osure time: Type: Res	nicroorganism): > 1,000 mg/l 3 h piration inhibition Test Guideline 209

Persistence and degradability

No data available

Bioaccumulative potential

No data available

Mobility in soil

No data available

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods	
Waste from residues Contaminated packaging	Dispose of in accordance with local regulations. Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.



Enalapril Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2020/10/10
2.8	2021/04/09	734742-00012	Date of first issue: 2016/06/07

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Minister of Industry Regulation No. 23/M-IND/PER/4/2013 concerning the Revision of Minister of Industry Regulation No. 87/M-IND/PER/9/2009 concerning Globally Harmonized System of Classification and Labelling of Chemicals.

Regulation of the Minister of Health No. 472 of 1996 on the Safeguarding of Substances Hazardous to Health

Hazardous substances that must be registered . Not applica	Hazardous substances that must be registered	:	Not applicable
--	--	---	----------------

Government Regulation No. 74 of 2001 on the Management of Hazardous and Toxic Substances

Hazardous substances approved for use	:	Not applicable
Prohibited substances	:	Not applicable
Restricted substances	:	Not applicable

Regulation of the Minister of Trade No. 44 of 2009 on Procurement, Distribution and Supervision of Hazardous Materials

Type of Hazardous Materials Restricted to Import,	:	Not applicable
Distribution and Supervision		

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

Enalapril Formulation



Versio 2.8	on Revision Date: 2021/04/09		DS Number: 34742-00012	Date of last issue: 2020/10/10 Date of first issue: 2016/06/07			
16. OTHER INFORMATION							
Further information							
С	Sources of key data used to compile the Safety Data Sheet		Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen- cy, http://echa.europa.eu/				
Date format		:	yyyy/mm/dd				
F	Full text of other abbreviations						
-	ACGIH D OEL	:		eshold Limit Values (TLV) pational Exposure Limits			
-	ACGIH / TWA D OEL / NAB	:	8-hour, time-weig Long term expos	-			

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their



Enalapril Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2020/10/10
2.8	2021/04/09	734742-00012	Date of first issue: 2016/06/07

intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ID / EN